Compare
Celldex Therapeutics, Inc. vs Volitionrx Ltd vs Insight Molecular Diagnostics Inc. vs Aspira Women's Health Inc.
| Latest fiscal year | Celldex Therapeutics, Inc. CLDX | Volitionrx Ltd VNRX | Insight Molecular Diagnostics Inc. IMDX | Aspira Women's Health Inc. AWHL |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.54M | $1.73M | $4.05M | $9.22M |
| Revenue growth (YoY) | -78.0% | +40.0% | +115.6% | +0.4% |
| Gross margin | 87.1% (computed) | n/a | 56.7% | 64.2% |
| Operating margin | n/m | n/m | n/m | -85.9% |
| Net margin | n/m | n/m | n/m | -138.7% |
| Net income | -$258.76M | -$23.36M | -$50.22M | -$12.78M |
| EPS (Diluted) | -$3.90 | n/a | -$1.65 | -$0.37 |
| Operating cash flow | -$210.94M | -$19.68M | -$22.18M | -$7.03M |
| Free cash flow | -$213.66M | -$19.77M | -$25.37M | -$7.04M |
| Cash & equivalents | $28.87M | $1.12M | $11.58M | $1.75M |
| Total assets | $582.98M | $6.90M | $25.76M | $5.46M |
| Total liabilities | $55.82M | $42.49M | $57.22M | $12.39M |
| Shareholders' equity | $527.16M | -$34.25M | -$31.46M | -$6.93M |
| Return on year-end equity | -49.1% | n/a | n/a | n/a |
| Shares outstanding | 66.55M | 125.78M | 28.68M | 43.48M |
Revenue, most recent five fiscal years
| Fiscal year | Celldex Therapeutics, Inc. | Volitionrx Ltd | Insight Molecular Diagnostics Inc. | Aspira Women's Health Inc. |
|---|---|---|---|---|
| Latest | $1.54M Ended 2025-12-31 | $1.73M Ended 2025-12-31 | $4.05M Ended 2025-12-31 | $9.22M Ended 2025-12-31 |
| 1 year earlier | $7.02M Ended 2024-12-31 | $1.23M Ended 2024-12-31 | $1.88M Ended 2024-12-31 | $9.18M Ended 2024-12-31 |
| 2 years earlier | $6.88M Ended 2023-12-31 | $775.3K Ended 2023-12-31 | $1.50M Ended 2023-12-31 | $9.15M Ended 2023-12-31 |
| 3 years earlier | $2.36M Ended 2022-12-31 | $306.4K Ended 2022-12-31 | $958.0K Ended 2022-12-31 | n/a |
| 4 years earlier | $4.65M Ended 2021-12-31 | $90.0K Ended 2021-12-31 | $2.20M Ended 2021-12-31 | n/a |